Status: Recruiting
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries. After completing the pre-clinical studies, the investigators have initiated a phase I/II clinical trial to test the safety and efficacy of the adoptive transfer of autologous thyTreg to prevent rejection in heart transplant children. Condition or disease: Heart Transplantation Intervention/treatment: Regulatory T Cell (Treg) Infusion
Participants needed: 11
Trial details
Phase: Phase 1, Phase 2Age: Up to 2Biological sex: AllType: InterventionalSponsor: Rafael Correa-RochaUpdated: Feb 3, 2025Locations: 1
Eligibility criteria
Patient under two years of age, who meets all the necessary requirements to unde... [+2]
Patients with DiGeorge Syndrome, since their thymic function is affected. [+9]